CSL Behring using Albumedix tech to extend the half-life of new haemophilia drug
CSL Behring has opted to extend the half-life of its haemophilia B treatment Idelvion using a technology developed by Novozymes A/S subsidiary Albumedix.
Archives for March 21, 2016
UK CRO BioPharmaSpec eyes growth in India and Asia-Pacific
BioPharmaSpec has set up business development teams for the Indian and Asia-Pacific markets and predicted increased demand for biosimilar characterisation services.